Endo, Noven deal

ENDP received U.S. and Canadian rights to NOVN's transdermal fentanyl patch to manage chronic pain. NOVN redeived an $8 million payment and is eligible for an additional $5-$10 million. The companies hope to launch the patch in January 2005. The product is a generic version of Duragesic fentanyl transdermal system from Johnson & Johnson (JNJ, New Brunswick, N.J.). ...